AI That
Sees More
AI-powered solutions delivering smarter eyecare and deeper health insights—helping clinicians make better, evidence-based decisions at scale.
Founded in partnership with
Our Mission
Transforming Eye Disease Detection with AI
At Cascader, we harness the power of artificial intelligence to help clinicians — in hospitals and in primary care — optimise workflows and deliver better patient care.
Our mission is to use AI to enable safe, evidence-based decisions in high-volume, high-risk eye conditions, preventing avoidable sight loss.
We also harness oculomics for non-invasive, early detection of systemic diseases — driving a shift toward preventative healthcare.
The Name Behind the Vision
Inspired by Nature's Most Exceptional Vision
Our name, Cascader, was inspired by the vision of a cascading progression of use cases—starting with eye disease and expanding into systemic health applications.
Cascaders are a type of dragonfly drawn to fast-moving water (cascades), known for their exceptional vision—including 360-degree sight and the ability to see ultraviolet and infrared light.
In disease, a cascade of biological events often leads to organ damage and symptoms. Early detection enables early intervention. Like our namesake, Cascader can fly against the flow of this cascade, using our AI's exceptional vision to detect problems early.
Cascader. AI That Sees More.
Built on World-Class Research
Our AI is evidence-led—built on extensive peer-reviewed research and rigorous clinical validation to prioritise patient safety and measurable clinical outcomes.
Validation and Clinical Applicability of Whole-Volume Automated Segmentation of OCT in Retinal Disease Using Deep Learning
2021 Read publicationClinically Applicable Deep Learning for Diagnosis and Referral in Retinal Disease
2018 Read publicationDual Site External Validation of AI-Enabled Treatment Monitoring for Neovascular Age-Related Macular Degeneration in England
2025 Read publicationGuided by Clinicians & Engineers
Cascader's founding team brings together deep expertise across clinical, technical, and operational domains to deliver real-world solutions at scale.
Dr. Peter Thomas
Dr Peter Thomas brings extensive experience in developing and delivering innovative healthcare services powered by technology, leading digital transformation programmes, and holding executive and national leadership roles within the NHS.
LinkedIn
Prof. Pearse Keane
Professor Pearse Keane is a top expert in eye-related artificial intelligence and Oculomics. He has done important research at Moorfields and UCL IoO. He helped create RETFound, the first major model for eye care, and has done a lot of work to shape the area of Oculomics.
LinkedIn
Ege Ilicak
Ege Ilicak, Chief Operating Officer, brings 15+ years of experience in the medical engineering field, from hands-on software development to managing large-scale projects and building quality management systems to bring healthcare innovations successfully to market.
LinkedInWorld-Class Institutional Backing
This new venture represents the next step in our commitment to translating world-class clinical research into tangible benefits for patients and the NHS.
Chief Executive, Moorfields Eye Hospital
Cascader reflects our shared vision of how AI and ocular data can reshape eyecare and enable new frontiers in precision medicine.
CEO, Topcon Healthcare
Partnering with industrial leaders in the new area of oculomics should accelerate routes to market for AI technologies and break down the barriers of AI applications in healthcare.
Associate Director, UCLB
Our Founding Partners
Latest from Cascader
Updates from our publications, product launches, and industry collaborations.
Reinventing the Eye Exam with Artificial Intelligence
Keane, P.A. Reinventing the eye exam with artificial intelligence. Nat Med (2025).
Pearse A. Keane’s Nature Medicine piece, Reinventing the eye exam with artificial intelligence, outlines how ophthalmology — buoyed by ubiquitous OCT imaging and large-scale datasets — is poised for transformative AI-driven change.
Keane traces progress from the 2018 Moorfields–UCL–DeepMind study to newer foundation-model work (RETFound) and the INSIGHT imaging bioresource, now holding tens of millions of ophthalmic images, which together enable diagnostic automation and “oculomics” insights.
He emphasises the hard work of translating algorithms into routine care — the shift from “idea → algorithm” to “code → clinic” — and highlights Cascader, a May 2025 Moorfields–UCL–Topcon venture he co-founded to accelerate clinical deployment. The article centres on patient impact as the ultimate measure of progress.
Read the articleUpcoming Events
IPS XXVIth Visual Field & Imaging Symposium
Bern, Switzerland · 202626th Euretina Congress
Vienna, Austria · 2026Our Path Forward
We'd like to share a glimpse of our current developments — and how we see Cascader enhancing healthcare in the months ahead.
Macular Decision Support
In DevelopmentMacular and Glaucoma Disease Support
Coming SoonCardiovascular and Neurological Oculomic Disease Detection
On the HorizonGet in Touch
Contact Our Team
For partnerships, product enquiries, press, research collaborations, or general questions — we'd love to hear from you.
info@cascader.ai